Warsaw, Poland, 13 June 2019 - Generic, biosimilar and value added medicine manufacturers deliver increased access to medicines worldwide. This access could be threatened by shortsighted cost-containment policies that make manufacturing and supply unsustainable. Focused pharmaceutical policies based on healthy competition, regulatory convergence, biosimilar medicines uptake and continuous innovation will deliver efficiency for healthcare, improved access to medicines and opportunities for manufacturers to invest for the future.
Geneva, 20 May 2019 - Generic and biosimilar medicines have improved the quality of life of patients all over the world by increasing access to high-quality medicines. It is useful to report data that shows the actual impact of generic and biosimilar medicines in everyday life.
Geneva, 27 February 2019 - The International Generic and Biosimilar medicines Association (IGBA) welcomes Health Canada’s decision to proceed with a biologic naming policy that identifies all biologic medicines, including biosimilars, by their unique brand name and non-proprietary (common) name, without the addition of a product-specific suffix. Health Canada made the decision following a domestic consultation process with stakeholders.
- Statement on the Passing of Dilip Shah
- Suzette Kox nominated as Secretary General of the International Generic and Biosimilar medicines Association
- IGBA Reflection Paper on waiving bridging studies for biosimilar medicines applications
- IGBA Position on Identification of Biological, including Biosimilar Medicines 2018 Update of Facts & Figures